美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

RayzeBio, Inc.

62.49

0.0000

成交量：- -

成交額：1,733.29萬

市值：37.44億

市盈率：-7.13

高：62.49

開：62.49

低：62.49

收：62.49

52周最高：62.51

52周最低：17.95

股本：5,991.95萬

流通股本：3,481.97萬

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):-8.7663

每股收益(LYR):-19.8964

淨資產收益率：--

總資產收益率：--

市淨率：6.51

市盈率(LYR):-3.14

資料載入中...

總覽公司新聞公告

公司資料

公司名字：

RayzeBio, Inc.

交易所：

NASDAQ

成立時間：

- -

員工人數：

- -

公司地址：

- -

官網：

http://rayzebio.com

郵編：

- -

電話：

- -

傳真：

- -

簡介：

RayzeBio, Inc.於2020年1月2日在特拉華州成立，總部設在加利福尼亞州聖地亞哥。該公司正在建立一家垂直整合的放射性藥物治療公司。該公司在3期臨床試驗中領導項目。該公司在具有重大市場機會的治療領域創建了多種候選藥物的管道。該公司最初的重點是建立一個市場領先的生長抑素受體2型，或SSTR2，專營權。隨着針對SSTR2的多種診斷和治療商業產品的出現，它是一種在多種實體瘤中表達的經臨床驗證的靶點。該公司的主要候選藥物RYZ101被設計用於向過度表達SSTR2的腫瘤遞送一種高效的α粒子放射性同位素Actinium 225或Ac225。RYZ101由與Ac225結合的多肽結合劑DOTATATE和螯合劑組成。美國食品和藥物管理局（FDA）已批准將DOTATATE用作SSTR2診斷成像和治療劑的多肽結合劑。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/RYZB/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RYZB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RYZB\",,,,,undefined,":{"symbol":"RYZB","market":"US","secType":"STK","nameCN":"RayzeBio, Inc.","latestPrice":62.49,"timestamp":1708722000000,"preClose":62.49,"halted":3,"volume":0,"delay":0,"floatShares":34819731,"shares":59919502,"eps":-8.766259,"marketStatus":"停牌","change":0,"latestTime":"08-08 09:19:57 EDT","open":62.49,"high":62.49,"low":62.49,"amount":17332947.2238,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-8.766259,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1754659800000},"marketStatusCode":1,"adr":0,"listingDate":1694750400000,"exchange":"NASDAQ","adjPreClose":62.49,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RYZB\",,,,,undefined,":{"symbol":"RYZB","floatShares":34819731,"roa":"--","roe":"--","lyrEps":-19.896435,"shares":59919502,"dividePrice":0,"high":62.49,"amplitude":0,"preClose":62.49,"low":62.49,"week52Low":17.95,"pbRate":"6.51","week52High":62.51,"institutionHeld":0,"latestPrice":62.49,"eps":-8.766259,"divideRate":0,"volume":0,"delay":0,"ttmEps":-8.766259,"open":62.49,"prevYearClose":62.17},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RYZB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-02-27","symbol":"RYZB","reason":null,"defaultRemindTime":1709044200000,"announcedDate":"2024-02-23","type":"delisting","dateTimestamp":1709010000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RYZB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RYZB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.5,"hold":0.25,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":4,"updateTime":1703998800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/RYZB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"RYZB","date":"2024-02-23","current":-58.953302,"percent":0.150538,"low":-59.59825,"twenty":-58.87593,"median":-24.211616,"eighty":-17.264309,"high":-1.756766,"avg":-35.263311,"sd":19.858488,"marketCap":3743770484},"quantilePoints":[{"date":"2023-09-15","current":-15.14118,"twenty":-15.14118,"median":-15.14118,"eighty":-15.14118,"marketCap":995683968},{"date":"2023-09-20","current":-18.514298,"twenty":-19.387439,"median":-18.514298,"eighty":-16.490427,"marketCap":1217500229},{"date":"2023-09-27","current":-15.57018,"twenty":-18.805345,"median":-15.830944,"eighty":-15.48438,"marketCap":1023895013},{"date":"2023-10-06","current":-16.874003,"twenty":-18.578227,"median":-16.874003,"eighty":-15.726638,"marketCap":1109634466},{"date":"2023-10-13","current":-17.244121,"twenty":-18.019686,"median":-17.059062,"eighty":-16.037874,"marketCap":1133973408},{"date":"2023-10-20","current":-16.402945,"twenty":-18.125675,"median":-17.244121,"eighty":-16.312098,"marketCap":1078657632},{"date":"2023-10-27","current":-15.940297,"twenty":-18.051651,"median":-17.033827,"eighty":-16.175827,"marketCap":1048233955},{"date":"2023-11-03","current":-17.277768,"twenty":-17.762286,"median":-16.941298,"eighty":-16.128721,"marketCap":1136186039},{"date":"2023-11-10","current":-16.815121,"twenty":-18.272039,"median":-17.138974,"eighty":-16.290227,"marketCap":1105762362},{"date":"2023-11-17","current":-1.756766,"twenty":-18.272039,"median":-17.033827,"eighty":-16.128721,"marketCap":111561655},{"date":"2023-11-24","current":-21.61684,"twenty":-18.49411,"median":-17.244121,"eighty":-16.204427,"marketCap":1372755790},{"date":"2023-12-01","current":-22.532088,"twenty":-19.070104,"median":-17.33665,"eighty":-16.335651,"marketCap":1430877707},{"date":"2023-12-08","current":-24.994766,"twenty":-21.324338,"median":-17.555357,"eighty":-16.402945,"marketCap":1587267607},{"date":"2023-12-15","current":-25.098557,"twenty":-21.656469,"median":-17.929699,"eighty":-16.719227,"marketCap":1593858753},{"date":"2023-12-22","current":-26.372356,"twenty":-22.762315,"median":-18.23671,"eighty":-16.811756,"marketCap":1674750080},{"date":"2023-12-29","current":-59.271474,"twenty":-24.09084,"median":-18.463828,"eighty":-16.818486,"marketCap":3763975660},{"date":"2024-01-05","current":-59.434862,"twenty":-24.90041,"median":-18.674121,"eighty":-16.823533,"marketCap":3774351464},{"date":"2024-01-12","current":-59.406029,"twenty":-25.381623,"median":-19.033195,"eighty":-16.840356,"marketCap":3772520440},{"date":"2024-01-19","current":-58.415476,"twenty":-34.75867,"median":-20.538426,"eighty":-16.867274,"marketCap":3709616368},{"date":"2024-01-26","current":-58.57588,"twenty":-58.438121,"median":-21.437564,"eighty":-16.927839,"marketCap":3719802684},{"date":"2024-02-02","current":-58.623058,"twenty":-58.579654,"median":-21.715913,"eighty":-17.008592,"marketCap":3722798659},{"date":"2024-02-09","current":-58.755155,"twenty":-58.615509,"median":-22.532088,"eighty":-17.032145,"marketCap":3731187389},{"date":"2024-02-16","current":-58.887253,"twenty":-58.764591,"median":-23.805886,"eighty":-17.202062,"marketCap":3739576119},{"date":"2024-02-23","current":-58.953302,"twenty":-58.87593,"median":-24.211616,"eighty":-17.264309,"marketCap":3743770484}],"updateTime":1754658609541},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://rayzebio.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0003},{"period":"1month","weight":0.0192},{"period":"3month","weight":0.1203},{"period":"6month","weight":0.0524},{"period":"1year","weight":0.219},{"period":"ytd","weight":0.0788}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"RayzeBio, Inc.於2020年1月2日在特拉華州成立，總部設在加利福尼亞州聖地亞哥。該公司正在建立一家垂直整合的放射性藥物治療公司。該公司在3期臨床試驗中領導項目。該公司在具有重大市場機會的治療領域創建了多種候選藥物的管道。該公司最初的重點是建立一個市場領先的生長抑素受體2型，或SSTR2，專營權。隨着針對SSTR2的多種診斷和治療商業產品的出現，它是一種在多種實體瘤中表達的經臨床驗證的靶點。該公司的主要候選藥物RYZ101被設計用於向過度表達SSTR2的腫瘤遞送一種高效的α粒子放射性同位素Actinium 225或Ac225。RYZ101由與Ac225結合的多肽結合劑DOTATATE和螯合劑組成。美國食品和藥物管理局（FDA）已批准將DOTATATE用作SSTR2診斷成像和治療劑的多肽結合劑。","exchange":"NASDAQ","name":"RayzeBio, Inc.","nameEN":"RayzeBio, Inc."}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"RYZB\",market:\"US\",,,undefined,":null}}